Build1 publisher3 min readPublished Updated
K261580 stretches ZBPro's cleared ECG window from 48 hours to 14 days
ZBeats' second FDA clearance this year moves ZBPro Diagnostic out of Holter-only labeling and into 14-day patch recordings. Adoption now turns on which recorders the software is cleared to read.
The Engineer · Build desk
What happened
- ZBeats said on September 15th that the FDA granted 510(k) clearance K261580 for ZBPro Diagnostic v2.0, covering ECG recordings that range from one minute to 14 days.
- The expanded scope includes wearable patches as well as Holter configurations, according to the company's announcement.
- ZBPro runs retrospective beat and rhythm analysis on recordings from supported hardware, with atrial fibrillation detection, a signal-processing feature ZBeats calls NoiseGuard, and technician tools for review, edits and reports.
Compiled by The EngineerSomething wrong?How this is made
Why it matters
- constraint Because a 510(k) clears the configurations named in the labeling, a patch maker's device is in scope only if ZBeats validated it, and detector accuracy does not settle that.
- decision Monitoring centers running mixed fleets now choose between one analysis layer and per-recorder software, and the deciding input is the supported-device list.
- exposure A 14-day record is seven times the longest window ZBeats had cleared, so any per-hour false-positive rate lands on the technician who must review and sign the report.
One minute to 14 days is a cleared range spanning a factor of 20,160 [1]. The short end is a consumer-wearable artifact, and Fang's announcement names consumer wearables as a target [4]. The long end is 336 hours of continuous signal that a technician then has to review, edit and turn into a report, which is what ZBPro's tooling is built for [3][2]. In the first version's labeling, the interpretation was advisory and not intended as the sole basis for diagnosis [8].
The first clearance was narrower in ways that decide integration work. The FDA summary limited ZBPro Diagnostic to retrospective 24- or 48-hour recordings from three-lead and five-lead Holter systems using specified electrode and lead configurations, and the labeling excluded wearable patches, multi-lead analysis, pediatric patients and paced recordings [5][6]. That clearance is dated July 10, 2025, and the new one was announced on September 15, 67 days later [1][3].
Scope in a 510(k) lives in the labeling. The clearance itself is a finding of substantial equivalence to a legally marketed predicate device, which the FDA distinguishes from premarket approval [10]. Substantial equivalence is a comparison to a predicate, not a certificate that the software parses your patch's file format. The question a patch maker has is whether its electrode geometry and lead configuration sit inside the set ZBeats validated. The announcement does not list v2.0's supported recorders or say whether the pediatric and paced-patient exclusions carried over.
"By separating ECG intelligence from the hardware, ZBPro creates a flexible foundation for clinical research, monitoring centers, and consumer wearables," Fang said in the announcement [4]. The predicate ZBeats used for its first clearance was the Cardiologs Holter Platform, a cloud ECG analysis system that already accepted data from several categories of ambulatory recording equipment [9].
The customer case is real enough: according to runtimewire.com, which reported the clearance from ZBeats' release, ambulatory ECG services increasingly take data from a mix of traditional Holters, adhesive patches and third-party devices, and a software layer that accepts those inputs lets a monitoring center standardize analysis and technician workflow without replacing every recorder [16]. The same account says interoperability and workflow economics will decide whether the independent software layer wins deployments [11].
I would expect validation labor to be the binding constraint. Every additional recorder is bench work and a submission decision, and a 2024 Stony Brook University profile counted seven full-time and four part-time workers at ZBeats, eleven people in all [13][4]. The company raised $1.25 million on November 1, 2021 in a round led by Camellia Venture Capital, earmarked for product development and regulatory submissions, and took a 2022 federal small-business award for feasibility testing of cloud-based ECG analysis for long-term ambulatory monitoring [12][14].
What to watch
- The FDA's 510(k) summary for K261580, once posted, will name the predicate and the recording configurations ZBeats validated.
- A named patch or recorder vendor announcing ZBPro as its analysis layer would test the interoperability claim in the field.
- Hiring or funding aimed at validation capacity, which is what adding each new supported recorder costs an eleven-person company.